Journal
JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/jcm11051198
Keywords
stroke; platelet proteome; biomarkers; platelets; thymidine phosphorylase 4; proteomics; drug target; human
Categories
Funding
- Polish Ministry of Science and Higher Education [IP2012009472 P-4/MNiSW/2013]
Ask authors/readers for more resources
The aim of this dynamic LC-MS proteomic study in human platelets was to identify potential protein candidates for biomarkers of acute ischemic stroke (AIS), assess their changes during the acute phase of stroke, and define new drug targets. The study found differences in platelet proteins between AIS patients and healthy controls, and identified Thymidine Phosphorylase 4 (TYMP-4) as a promising drug target for the management or prevention of ischemic stroke.
(1) Objective: The aim of this dynamic LC-MS (liquid chromatography and mass spectrometry) human platelet proteomic study was to identify the potential proteins candidates for biomarkers of acute ischemic stroke (AIS), their changes during the acute phase of stroke and to define potential novel drug targets. (2) Methods: A total of 32 patients (18-80 years old) were investigated that presented symptoms of AIS lasting less than 24 h from the onset, confirmed by neurological examination and/or new cerebral ischemia visualized in the CT (computed-tomography) scans. The analysis of platelet proteome was performed using LC-MS at baseline, and then on the third and seventh day from the onset of symptoms. The control group was demographically matched without any clinical signs of acute brain injury. (3) Results: The differences between platelets, at 24 h after first symptoms of stroke subjects and the control group included: beta-amyloid A4 and amyloid-like protein 2, coactosin-like protein, thymidine phosphorylase 4 (TYMP-4), interferon regulatory factor 7 (IRF7), vitamin K-dependent protein S, histone proteins (H2A type 1 and 1-A, H2A types 2B and J, H2Av, -z, and -x), and platelet basic protein. The dynamic changes in the platelet protein concentration involved thrombospondin-1, thrombospondin-2, filamin A, B, and C. (4) Conclusions: This is the first human dynamic LC-MS proteomic study that differentiates platelet proteome in the acute phase of ischemic stroke in time series and compares the results with healthy controls. Identified proteins may be considered as future markers of ischemic stroke or therapeutic drug targets. Thymidine phosphorylase 4 (TYMP-4) holds promise as an interesting drug target in the management or prevention of ischemic stroke.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available